BOLD
Boundless Bio, Inc.
Key Financials
Net Income
$-58197000
↑ 11.0%
Operating Income
$-63552000
↑ 13.3%
EPS (Diluted)
$-2.60
↑ 32.5%
Total Liabilities
$58.4M
↑ 4.7%
Shareholders' Equity
$98.7M
↓ 34.5%
Cash & Equivalents
$17.9M
↓ 32.8%
Total Assets
$157.1M
↓ 23.9%
Operating Cash Flow
$-46661000.00
↑ 23.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/8/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| ARS | 4/28/2026 | View on SEC |
| DEFA14A | 4/28/2026 | View on SEC |
| DEF 14A | 4/28/2026 | View on SEC |
| 8-K | 4/13/2026 | View on SEC |
| 10-K | 3/9/2026 | View on SEC |
| 8-K | 3/9/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BOLD |
| Company Name | Boundless Bio, Inc. |
| CIK | 1782303 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 766-9912 |